Lusefi (luseogliflozin) / Taisho 
Welcome,         Profile    Billing    Logout  
 1 Disease   0 Trials   0 Trials   218 News 


123»
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    VASCULAR PROTECTIVE EFFECTS OF SGLT2 INHIBITION IN AD/ADRD () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_1113;    
    TgF344-AD rats were orally administered luseogliflozin (20 mg/kg/day) for 3 months... These findings suggest that SGLT2 inhibition is a promising therapeutic approach for addressing vascular dysfunction in AD.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    Journal:  Telogen Effluvium Following the Treatment of Euglycemic Diabetic Ketoacidosis in a Patient With Heavy Soft Drink Intake: A Case Report. (Pubmed Central) -  Nov 19, 2024   
    This case report discusses a man with type 2 diabetes mellitus associated with heavy soft drink intake who developed telogen effluvium following treatment for euglycemic diabetic ketoacidosis with luseogliflozin...Physical wasting due to hyperglycemia and ketoacidosis was assumed to have triggered hair loss, resulting in rapid weight loss. Investigating the triggers associated with alopecia is crucial for diagnosing and treating telogen effluvium.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    SGLT2 Inhibitors Reduce the Progression from AKI to CKD by Inhibiting Ferroptosis (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_936;    
    Luseogliflozin mitigates the progression from AKI to CKD by modulating metabolic pathways and reducing oxidative stress and ferroptosis. This study suggests a potential therapeutic role for SGLT2 inhibitors in the management of AKI, advocating for further clinical investigation.
  • ||||||||||  Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Lusefi (luseogliflozin) / Taisho
    Journal:  The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors. (Pubmed Central) -  Jun 20, 2024   
    In vitro study, both inhibitors attenuated the lipopolysaccharide-induced activation of primary microglia, along with morphological changes toward an inactive form, suggesting the direct inhibitory effect of SGLT2 inhibitors on microglia. In summary, SGLT2i may directly prevent early pathogenic mechanisms, thereby potentially playing a role in preventing DR.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    Preclinical, Journal:  Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats. (Pubmed Central) -  May 30, 2023   
    Muscle atrophy in streptozotocin-induced hyperglycemic model rats was inhibited by the suppression of hyperglycemia using luseogliflozin, which consequently suppressed hyperglycemia-mediated increase in the levels of advanced glycation end products (AGEs) and activated the protein degradation pathway in muscle cells. Treatment with luseogliflozin can restore the hyperglycemia-induced loss in the muscle mass to some degree partly through the inhibition of AGEs-induced or homeostatic disruption of mitochondria-induced activation of muscle degradation.
  • ||||||||||  Journal:  New Synthesis of Diarylmethanes, Key Building Blocks for SGLT2 Inhibitors. (Pubmed Central) -  May 22, 2023   
    Treatment with luseogliflozin can restore the hyperglycemia-induced loss in the muscle mass to some degree partly through the inhibition of AGEs-induced or homeostatic disruption of mitochondria-induced activation of muscle degradation. The new protocol proceeded more cleanly than the previous methods employing AlCl and BF
  • ||||||||||  Lusefi (luseogliflozin) / Taisho, Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
    Protective Effects of DPP-4 Inhibitor and SGLT2 Inhibitor on Pancreatic  (Poster Halls B-C; [Board No. 886]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1460;    
    Improvement effects on DI 0-120 were almost identical between luseogliflozin and teneligliptin. On the other hand, burden on ?-cells was mitigated only in luseogliflozin group.
  • ||||||||||  Review, Journal:  The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. (Pubmed Central) -  Dec 23, 2022   
    However, studies of ipragliflozin and luseogliflozin, agents approved outside the United States (U.S.), reported different outcomes relative to pivotal trials and failed to realize benefits in the HFpEF population...In the U.S., high cost and administrative hurdles may contribute to decreased patient and clinician uptake of this drug class. Future trial results and clinical experience with SGLT2 inhibitors may lead to expanded use and greater uptake among patients with heart failure.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
    Review, Journal:  Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms. (Pubmed Central) -  Dec 20, 2022   
    It is important to remember that some studies have not shown any beneficial effects of SGLT2i on kidney fibrosis. Given this background, in the current review, we have summarized the studies and pathophysiologic aspects of SGL2 inhibition on renal fibrosis in various CKD models and tried to explain the potential reasons for contrasting findings.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    Journal:  Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet. (Pubmed Central) -  Nov 22, 2022   
    Conclusions The glucose-lowering effect of luseogliflozin was enhanced with high-carbohydrate intake more than with low-carbohydrate intake. In this study, the observed number was small; however, combined treatment with an incretin modulator and luseogliflozin had an additive effect in high- versus low-carbohydrate intake, indicating the possible effectiveness of the combined therapy.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    Biomarker, Clinical, Journal:  Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. (Pubmed Central) -  Sep 20, 2022   
    No significant difference was observed between the two groups in the adiponectin and high-sensitivity C-reactive protein levels after 12 weeks compared to the baseline levels (percent change, - 1.6% vs. - 4.0% and 22.5% vs. 10.0%; p = 0.52 and p = 0.55, respectively). In conclusion, in patients with type-2 diabetes and heart failure, compared to voglibose, luseogliflozin did not significantly improve the high-risk lipoprotein profile including malondialdehyde LDL and small-dense LDL cholesterol or the levels of inflammatory markers, including adiponectin and high-sensitivity C-reactive protein.Trial registration: Trial number: UMIN-CTR, UMIN000018395; Registered 23 July 2015; URL: https://www.umin.ac.jp/ctr/index.htm .
  • ||||||||||  Lusefi (luseogliflozin) / Taisho, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Conducting Budget Impact Analysis (BIA) for Multiple HTA of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—There Is More Than Meets the Eye (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2449;    
    Stakeholders propose widening access to empagliflozin in primary care settings, or using dapagliflozin or luseogliflozin as alternatives for ≥1 indications in hospitals or primary care. Though complex and time-consuming, the simulation of a wide range of practical uptake scenarios has enabled this comprehensive BIA as a useful decision-making aid.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    Journal:  Challenges in drug discovery research and the effects of SGLT2 inhibitor against diabetic kidney disease (Pubmed Central) -  Jul 6, 2022   
    In order to verify the effect of SGLT2 inhibitors on diabetic complications, we examined the effects of luseogliflozin using two kinds of animal models expressing the progressive renal injury including the advanced features of diabetic kidney disease similar to patients. Luseogliflozin and combination therapy with ACE inhibitor prevented the progression of renal injury in these animal models, and the result suggests that treatment with SGLT2 inhibitors could be a candidate of therapeutic option for diabetic kidney disease.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Journal:  Dapagliflozin Attenuates Contrast-Induced Acute Kidney Injury by Regulating the HIF-1α/HE4/NF-κB Pathway. (Pubmed Central) -  Jun 9, 2022   
    Previous studies have shown that hypoxia activates HIF-1α/HE4/NF-κB to enhance renal fibrosis, and the SGLT-2 inhibitor luseogliflozin inhibits hypoxia-inducible factor (HIF)-1α expression to reduce the progression of diabetic nephropathy...CI-AKI was induced by intravenously injecting indomethacin, N-nitro-l-arginine methyl ester, and iohexol...Serum creatinine, urea nitrogen, TUNEL-positive tubular cells, HIF-1α, HE4, NF-κB expression, and histopathological scores were increased in DCM rats compared with C, D, and DDCM rats (P < 0.01). Thus, dapagliflozin may ameliorate CI-AKI via suppression of HIF-1α/HE4/NF-κB signaling in vitro and in vivo.